Bristol-Myers Squibb Co (BMY) : Boyer Corporon Wealth Management scooped up 29,938 additional shares in Bristol-Myers Squibb Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 64,357 shares of Bristol-Myers Squibb Co which is valued at $4.6 Million.Bristol-Myers Squibb Co makes up approximately 2.60% of Boyer Corporon Wealth Management’s portfolio.
Other Hedge Funds, Including , Trustmark National Bank Trust Department reduced its stake in BMY by selling 2,020 shares or 3.02% in the most recent quarter. The Hedge Fund company now holds 64,864 shares of BMY which is valued at $4.6 Million. Bristol-Myers Squibb Co makes up approx 0.63% of Trustmark National Bank Trust Department’s portfolio. Novare Capital Management sold out all of its stake in BMY during the most recent quarter. The investment firm sold 4,687 shares of BMY which is valued $333,621.Ftb Advisors boosted its stake in BMY in the latest quarter, The investment management firm added 3,404 additional shares and now holds a total of 25,390 shares of Bristol-Myers Squibb Co which is valued at $1.8 Million. Bristol-Myers Squibb Co makes up approx 0.20% of Ftb Advisors’s portfolio.Investment Partners Ltd Oh Adv boosted its stake in BMY in the latest quarter, The investment management firm added 30,021 additional shares and now holds a total of 50,706 shares of Bristol-Myers Squibb Co which is valued at $3.6 Million. Bristol-Myers Squibb Co makes up approx 2.29% of Investment Partners Ltd Oh Adv’s portfolio.Smith Asset Management Group Lp boosted its stake in BMY in the latest quarter, The investment management firm added 18,080 additional shares and now holds a total of 183,660 shares of Bristol-Myers Squibb Co which is valued at $13.1 Million. Bristol-Myers Squibb Co makes up approx 0.39% of Smith Asset Management Group Lp’s portfolio.
Bristol-Myers Squibb Co opened for trading at $70.55 and hit $71.16 on the upside on Friday, eventually ending the session at $70.77, with a gain of 0.63% or 0.44 points. The heightened volatility saw the trading volume jump to 51,64,177 shares. Company has a market cap of $118,137 M.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.65. The company had revenue of $4391.00 million for the quarter, compared to analysts expectations of $4268.65 million. The company’s revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.71 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Company shares were Reiterated by UBS on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 80 from a previous price target of $73 .Company shares were Reiterated by Barclays on Apr 29, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 75 from a previous price target of $70 .Societe Generale Initiated Bristol-Myers Squibb Co on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $48.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.